Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
scPharmaceuticals ( (SCPH) ) just unveiled an update.
On June 3, 2025, scPharmaceuticals Inc. held its Annual Meeting of Stockholders, with 35,156,523 shares represented, accounting for approximately 69.91% of the company’s outstanding common stock. During the meeting, William T. Abraham, M.D., Mette Kirstine Agger, and Minnie Baylor-Henry were elected as Class II Directors, and the appointment of RSM US LLP as the independent registered public accounting firm was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis.
The most recent analyst rating on (SCPH) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on scPharmaceuticals stock, see the SCPH Stock Forecast page.
Spark’s Take on SCPH Stock
According to Spark, TipRanks’ AI Analyst, SCPH is a Neutral.
scPharmaceuticals’ stock score is primarily influenced by its challenging financial position, with high debt levels and negative cash flows. While technical indicators suggest strong momentum, the potential near-term pullback due to overbought conditions and the negative valuation metrics indicate caution. The earnings call provided positive insights, but its impact is not included in the weighted score.
To see Spark’s full report on SCPH stock, click here.
More about scPharmaceuticals
Average Trading Volume: 433,679
Technical Sentiment Signal: Buy
Current Market Cap: $221.7M
See more data about SCPH stock on TipRanks’ Stock Analysis page.